Debra Gussman, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 19 Davis Ave Fl 7, Neptune, NJ 07753 Phone: 732-776-3797 Fax: 732-776-3796 |
Stephanie Sansone, Obstetrics & Gynecology - Female Pelvic Medicine and Reconstructive Surgery Medicare: Medicare Enrolled Practice Location: 19 Davis Ave Fl 7, Neptune, NJ 07753 Phone: 732-776-3797 Fax: 732-776-3796 |
William J Mann, MD Obstetrics & Gynecology - Gynecologic Oncology Medicare: Medicare Enrolled Practice Location: 3520 Route 33, Neptune, NJ 07753 Phone: 732-897-7944 Fax: 732-922-8264 |
Andrew N Blechman, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1944 Route 33, Neptune, NJ 07753 Phone: 732-776-3797 Fax: 732-776-3796 |
Dr. Jennifer E Powel, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 19 Davis Ave Fl 7, Neptune, NJ 07753 Phone: 732-776-4755 |
News Archive
Latest research from New Zealand's University of Otago is shedding new light on why and how cancer cells spread from primary tumours to other parts of the body. This phenomenon - known as metastasis - causes about 90 per cent of all cancer deaths.
The benefits of collaborative, multidisciplinary care of patients with complex autoimmune diseases like lupus and multiple sclerosis are just beginning to be appreciated by physicians. Hospital for Special Surgery in New York will present evidence of the advantages of such a specialized disease center dedicated to comprehensive lupus care at the 74th Annual Meeting of the American College of Rheumatology in Atlanta.
Chemotherapy-induced peripheral neuropathy, or CIPN, is a common side effect of cancer treatment that causes shooting or burning pain, numbness, tingling and cold sensitivity of the hands and feet for many cancer patients.
Golf Trust of America, Inc. announced that GTA's stockholders voted to approve the four proposals that were conditions to closing the previously-announced merger between GTA and Pernix Therapeutics, Inc. at a Special Meeting of Stockholders held earlier today.
MDRNA, Inc., a leading RNAi-based drug discovery and development company, today announced that the State Intellectual Property Office of the People's Republic of China (PRC) has issued a Notification of Granting Patent Rights for PRC 200480018784 which includes the use of nucleic acids, e.g., an siRNA, for the treatment of cancer. The patent describes modulation of claudins, which are proteins implicated in tumor progression and metastasis.
› Verified 4 days ago